BCBS North Carolina coverage for Wegovy (Heart

Employer / Commercial Insurance

Depends on your plan's benefit

Patient must have anti-obesity medication coverage benefits (criterion 7 of initial criteria; criterion 4 of continuation criteria)

What you need to qualify

Age 18 and older
BMI of 27 or higher
Established cardiovascular disease (MI, stroke, and PAD)
On guideline-directed medical therapy (optimized pharmacotherapy for established cardiovascular disease)

Qualification pathways

You can qualify through any one of these.

CV risk reduction — established cardiovascular disease with qualifying event

All of:

Patient is 18 years of age or older
Using medication to reduce risk of MACE (cardiovascular death, non-fatal MI, or non-fatal stroke)
Established cardiovascular disease (defined as: CAD, ACS, history of MI, stable or unstable angina, coronary or other arterial revascularization, prior PCI/CABG, stroke, TIA, carotid or other arterial stenosis, or PAD including aortic aneurysm, all of atherosclerotic origin)
BMI >= 27 kg/m2
Patient will use optimized pharmacotherapy for established cardiovascular disease in combination with Wegovy
Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
Requested medication will NOT be used concurrently with another weight loss medication
Patient has anti-obesity medication coverage benefits

Plus any one of:

History of myocardial infarction
History of stroke
Peripheral artery disease defined by intermittent claudication with ankle-brachial index < 0.85 at rest, peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease

Documentation to bring

Documentation of established cardiovascular disease (CAD, ACS, MI, angina, revascularization, PCI/CABG, stroke, TIA, carotid/arterial stenosis, or PAD of atherosclerotic origin)
Documentation of qualifying CV event history (MI, stroke, or PAD with ABI < 0.85, revascularization, or amputation)
Baseline BMI >= 27 kg/m2
Documentation of current use of optimized pharmacotherapy for established cardiovascular disease or clinical reason it is not appropriate
Documentation that patient is not concurrently using another GLP-1 receptor agonist
Documentation that patient is not concurrently using another weight loss medication
Confirmation of anti-obesity medication coverage benefits

Quantity limits

0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL — 4 pens per 28 days
1.5 mg tablet — 1 tablet per day
4 mg tablet — 1 tablet per day
9 mg tablet — 1 tablet per day

Approval and renewal

Initial approval: 6 months
Renewal: every 12 months
To renew, the plan looks for Patient must continue optimized pharmacotherapy for established CVD in combination with Wegovy AND demonstrate a positive clinical response. Initial CVD, BMI, and GDMT requirements are re-verified at continuation for this indication.

Not covered when

Concurrent use of another GLP-1 receptor agonist
Concurrent use of another weight loss medication

Policy note: Applies to both Wegovy injection (0.25mg–2.4mg) and Wegovy tablets. CV risk reduction indication requires established CVD with at least one specific qualifying event (MI, stroke, or PAD) plus BMI >= 27. 'Optimized pharmacotherapy' is not further specified in the policy. Excludes_diabetes is false — the policy does not exclude diabetic patients from this indication. Definition of established CVD was added June 2025.

Policy effective July 1, 2026 · verified July 16, 2026 · source: Pa policy

BCBS North Carolina coverage for Wegovy (Heart Disease Risk Reduction)